Areas of consensus at APCCC last year … see Table 1

So your sitemaster has been looking through the full report from the APCCC meeting held in Basel last year — as he promised he would. … READ MORE …

FamGenix — a family health history app

As the Democratic Party discovered this week in Iowa, apps can have problems. However, there are also apps that prove to be very useful straight out of the gate — and they can be improved over time too. … READ MORE …

Detailed data from the APCCC meeting in Basel now available

Last August your sitemaster attended and reported from the third iteration of the Advanced Prostate Cancer Consensus Conference (APCCC), held in Basel, Switzerland (see here, here, and here). … READ MORE …

ADT + darolutamide extends overall survival in men with nmCRPC

According to a media release issued by Bayer a couple of days ago, the combination of androgen deprivation therapy (ADT) + darolutamide (Nubeqa) extends overall survival “significantly” in men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …

A follow-up on active surveillance and the MEAL study

A couple of weeks ago, the full report on the Men’s Eating and Living (MEAL) study was published in the Journal of the American Medical Association. It has generated a lot of discussion, some of which is distinctly misguided. … READ MORE …

Beyond PSMA — FAPI theranostics

Ideally, a new diagnostic and therapy (“theranostic”) will have the following qualities:

  • It will be theranostic for all cancers (high sensitivity)
  • It will not be theranostic of anything that isn’t cancer (high specificity)

… READ MORE …

Why lutetium-177-PSMA treatment sometimes may not help, and may even harm

Lu-177-PSMA usually improves survival

We’ve seen in a couple of small trials in Germany and Australia that Lu-177-PSMA seemed to provide better than expected survival. … READ MORE … -p>

FDA approves enzalutamide for treatment of metastatic HSPC

Yesterday the U.S. Food and Drug Administration (FDA) approved the use of enzalutamide (Xtandi) for the treatment of metastatic, hormone-sensitive prostate cancer (mHSPC) — also known as metastatic, castration-rsensitive prostate cancer or mCSPC. … READ MORE …

Diabetes and risk for prostate cancer

There have long been suggestions that men already diagnosed with and receiving treatment for diabetes are at lower risk for a subsequent diagnosis of prostate cancer than non-diabetics. However, a very large, new, epidemiological analysis seems to suggest strongly that this may not be the case at all. … READ MORE …

Risk for prostate cancer in men under 40 years of age

A newly published paper by Blayer et al. in in the journal Cancer has stated that,

Worldwide, the incidence of prostate cancer has increased in all groups between ages 15 and 40 years and increased globally at a steady rate averaging 2% per year since 1990.

… READ MORE …

InfoLink information hiatus

Over the past month there have been no new postings to this web site. Your sitemaster apologizes for this hiatus.

The reasons are complex and include the sitemaster’s personal health status (nothing really serious but distinctly debilitating) and other business and personal pressures.

The current goal is to start to get things back on track as on Monday, November 18, so please be patient with us for just a couple more days.

Gone but by no means forgotten

It is with great regret that we must report the demise — last Saturday — of Dr. Gerald (“Gerry”) Chodak — formerly a professor of urology at the University of Chicago Pritzker School of Medicine. … READ MORE …

“Adjuvant” similar to “early salvage” radiation outcome in meta-analysis

Although at least three randomized clinical trials have told us that adjuvant radiation after prostatectomy often affords better results than just taking a “wait-and-see” approach, … READ MORE …

Data from the PROfound trial reported at ESMO

From a report presented by Hussain yesterday at the annual meeting of the European Society for Medical Oncology (ESMO) we gained detailed insight into the results of the PROfound trial of olaparib (Lynparza), which had been said to be positive last August. … READ MORE …

Risk for early onset prostate cancer MAY BE increased in some infertile men

In posting the following commentary, we wish to be VERY clear that, at this time, there is no definitive evidence that there is a causal relationship between male infertility and risk for prostate cancer, but this does appear to be a POSSIBILITY. … READ MORE …